Evaluation of drug responses in acral melanoma cell lines using quantitative phase imaging

Acral melanoma often presents at advanced stages and responds poorly to standard therapies, necessitating targeted treatments. Using quantitative phase imaging (QPI), we evaluated the effects of Lenvatinib, Sunitinib, and Apatinib on six primary acral melanoma cultures. Lenvatinib showed minimal impact except in HCI-ASM020 and HCI-AM087 at 20 µM. Apatinib and Sunitinib were cytotoxic at 40 and 50 µM, respectively. AM088 cells had delayed responses to Sunitinib (15 hours) and Apatinib (23 hours). EC50 values ranged from 0.01 µM to 136 µM. These results underscore QPI's potential in screening and personalizing acral melanoma therapies.